Strickler, J., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., … Bekaii-Saab, T. (2022). LBA-2 Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC. In Annals of Oncology (Vol. 33, pp. S375–S376). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.04.440

Strickler, J., A. Cercek, S. Siena, T. André, K. Ng, E. Van Cutsem, C. Wu, et al. “LBA-2 Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC.” In Annals of Oncology, 33:S375–76. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.04.440.

Strickler J, Cercek A, Siena S, André T, Ng K, Van Cutsem E, et al. LBA-2 Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC. In: Annals of Oncology. Elsevier BV; 2022. p. S375–6.

Strickler, J., et al. “LBA-2 Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S375–76. Crossref, doi:10.1016/j.annonc.2022.04.440.

Strickler J, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson A, Hubbard J, Coveler A, Fountzilas C, Kardosh A, Kasi P, Lenz H, Ciombor K, Elez E, Bajor D, Stecher M, Feng W, Bekaii-Saab T. LBA-2 Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC. Annals of Oncology. Elsevier BV; 2022. p. S375–S376.